RT Journal Article
T1 Amyloid PET in primary progressive aphasia: case series and systematic review of the literature
A1 Villarejo Galende, Alberto
A1 Llamas Velasco, Sara
A1 Gómez Grande, Adolfo
A1 Puertas Martín, Verónica
A1 Contador, Israel
A1 Sarandeses Fernández, María Del Pilar
A1 González Sánchez, Marta
A1 Trincado, Rocío
A1 Pilkington, Patrick
A1 Ruiz Solís, Sebastián
A1 Pérez Martínez, David Andrés
A1 Herrero San Martín, Alejandro
AB Primary progressive aphasia (PPA) is considered a heterogeneous syndrome, with different clinical subtypes and neuropathological causes. Novel PET biomarkers may help to predict the underlying neuropathology, but many aspects remain unclear. We studied the relationship between amyloid PET and PPA variant in a clinical series of PPA patients. A systematic review of the literature was performed. Patients with PPA were assessed over a 2-year period and classified based on language testing and the International Consensus Criteria as non-fluent/agrammatic (nfvPPA), semantic (svPPA), logopenic variant (lvPPA) or as unclassifiable (ucPPA). All patients underwent a Florbetapir (18-F) PET scan and images were analysed by two nuclear medicine physicians, using a previously validated reading method. Relevant studies published between January 2004 and January 2016 were identified by searching Medline and Web of Science databases. Twenty-four PPA patients were included (13 women, mean age 68.8, SD 8.3 years; range 54–83). Overall, 13/24 were amyloid positive: 0/2 (0%) nfvPPA, 0/4 (0%) svPPA, 10/14 (71.4%) lvPPA and 3/4 (75%) ucPPA (p = 0.028). The systematic review identified seven relevant studies, six including all PPA variants and one only lvPPA. Pooling all studies together, amyloid PET positivity was 122/224 (54.5%) for PPA, 14/52 (26.9%) for nfvPPA, 6/47 (12.8%) for svPPA, 101/119 for lvPPA (84.9%) and 12/22 (54.5%) for ucPPA. Amyloid PET may help to identify the underlying neuropathology in PPA. It could be especially useful in ucPPA, because in these cases it is more difficult to predict pathology. ucPPA is frequently associated with amyloid pathology.
PB Springer
SN 0340-5354
YR 2016
FD 2016-11-04
LK https://hdl.handle.net/20.500.14352/117636
UL https://hdl.handle.net/20.500.14352/117636
LA eng
NO Villarejo-Galende, A., Llamas-Velasco, S., Gómez-Grande, A. et al. Amyloid pet in primary progressive aphasia: case series and systematic review of the literature. J Neurol 264, 121–130 (2017). https://doi.org/10.1007/s00415-016-8324-8
DS Docta Complutense
RD 16 jun 2026